Meeting
2017 ASCO Annual Meeting
Effect of TCHL-based therapy on immune cell content in on-treatment, neoadjuvant-treated HER2-positive breast cancer patients.
Authors
Niamh M. Keegan
St. James's Hospital, Dublin, Ireland
Niamh M. Keegan , Sinead Toomey , Joanna Fay , Stephen F. Madden , Bruce Moran , Malgorzata Milewska , Sudipto Das , Darran O'Connor , M. John Kennedy , Colm Power , Arnold D. Hill , Keith Egan , Ausra Teiserskiene , Elaine Kay , John Crown , Alex J Eustace , Bryan Hennessy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Citation
J Clin Oncol 35, 2017 (suppl; abstr 583)
DOI
10.1200/JCO.2017.35.15_suppl.583
Abstract #
583
Poster Bd #
183
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
The clinical impact of early immunological responses in human HER2-positive breast cancers on responsiveness to trastuzumab-based therapy.
First Author: Alex J Eustace
Poster
2016 ASCO Annual Meeting
Impact of somatic PIK3CA and ERBB family mutations on pathological complete reponse (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
First Author: Sinead Toomey
Poster
2016 ASCO Annual Meeting
Increased FoxP3 and PD-L1 in non-pCR tissue from early stage HER2 positive breast cancer patients treated with trastuzumab-pertuzumab based regimens.
First Author: Jeremy Meyer Force
Poster
2020 ASCO Virtual Scientific Program
Neoadjuvant TCH (docetaxel/darboplatin/trastuzumab) versus EC-TH (epirubicin/cyclophosphamide followed by docetaxel/ trastuzumab ) in patients with HER2-positive breast cancer (neoCARH): A randomised, open-label, multicenter, phase II trial.
First Author: Hong-Fei Gao